BERLIN, Germany, September 28, 2021 / B3C newswire / -- ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma company. The license covers the evaluation of the DirectedLuck Transposase technology in their cell line development processes.
DirectedLuck builds on a transposase's principle but with additional major improvements. It has been optimized to recognize specific chromatin marks, guiding the transgene to genomic regions with highest transcriptional activity, which ensures exceptionally high protein expression and maximum stability. The clone pools generated within days to weeks are highly representative of later clones. This reduces time and hands-on lab work for selecting superior clones for best titers, proven stability and product quality. The DirectedLuck Transposase is compatible with additional genetic elements in standard expression vector design and can be used with any host cell line from different species and tissue origin. DirectedLuck has been applied to develop cell lines for standard mAbs, complex glycoproteins and bispecifics and is also applicable beyond protein and virus production in cell therapy.
DirectedLuck is available for out-licensing. Furthermore, ProBioGen applies DirectedLuck as a standard tool in clients' service projects at no extra charge.
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen's CHO-RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
Dr. Gabriele Schneider
Chief Business Officer
+49 (0)30 3229 35 100
ProBioGen Press Contact
Keywords: Cell Line; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Transposases; Transgenes; Genetic Vectors; Epigenesis, Genetic; Technology; Recombinant Proteins; Biological Products; Productivity; Bioreactors; Commerce; Germany
Published by B3C newswire